FGEN beat EPS expectations by 45.36%
Nov 12, 2024, 11:31 PM
0.00%
What does FGEN do
FibroGen, headquartered in San Francisco, focuses on developing novel therapeutics for cancer and anemia, with key products including Pamrevlumab and Roxadustat. The company went public on November 14, 2014, and employs 486 staff.
FibroGen (FGEN) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, FibroGen's actual EPS was -$0.17, beating the estimate of -$0.31 per share, resulting in a 45.36% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.